
    
      The study will enroll up to 48 subjects, with up to 5 dose escalating cohorts of 6 open-label
      subjects enrolled for Type A-SLE and 3 dose escalating cohorts of 6 open-label subjects
      enrolled for Type B-Lupus Nephritis.

      Subjects will receive itolizumab administered subcutaneously every two weeks for a total of
      either 2 (Type A) or 13 (Type B) doses with 4 or 12 weeks of follow-up after the last dose of
      investigational product.
    
  